<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38675974</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16040634</ELocationID><Abstract><AbstractText>The Omicron variant of SARS-CoV-2, characterized by multiple subvariants including BA.1, XBB.1.5, EG.5, and JN.1, became the predominant strain in early 2022. Studies indicate that Omicron replicates less efficiently in lung tissue compared to the ancestral strain. However, the infectivity of Omicron in the gastrointestinal tract is not fully defined, despite the fact that 70% of COVID-19 patients experience digestive disease symptoms. Here, using primary human colonoids, we found that, regardless of individual variability, Omicron infects colon cells similarly or less effectively than the ancestral strain or the Delta variant. The variant induced limited type III interferon expression and showed no significant impact on epithelial integrity. Further experiments revealed inefficient cell-to-cell spread and spike protein cleavage in the Omicron spike protein, possibly contributing to its lower infectious particle levels. The findings highlight the variant-specific replication differences in human colonoids, providing insights into the enteric tropism of Omicron and its relevance to long COVID symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antia</LastName><ForeName>Avan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarado</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-8748-0761</Identifier><AffiliationInfo><Affiliation>Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Qiru</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3731-9950</Identifier><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casorla-Perez</LastName><ForeName>Luis A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Deanna L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonnek</LastName><ForeName>Naomi M</ForeName><Initials>NM</Initials><Identifier Source="ORCID">0000-0001-6530-4396</Identifier><AffiliationInfo><Affiliation>Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciorba</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-7656-0982</Identifier><AffiliationInfo><Affiliation>Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI167285</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000095022">Interferon Lambda</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="Y">Colon</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="Y">Epithelial Cells</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095022" MajorTopicYN="N">Interferon Lambda</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 Delta</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Omicron BA.1</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 WA1</Keyword><Keyword MajorTopicYN="N">human primary colonoids</Keyword><Keyword MajorTopicYN="N">interferon responses</Keyword><Keyword MajorTopicYN="N">intestinal infection</Keyword><Keyword MajorTopicYN="N">intestinal permeability</Keyword><Keyword MajorTopicYN="N">spike processing</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38675974</ArticleId><ArticleId IdType="pmc">PMC11055019</ArticleId><ArticleId IdType="doi">10.3390/v16040634</ArticleId><ArticleId IdType="pii">v16040634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO)  Coronavirus Disease 2019 (COVID-19) Dashboard.  [(accessed on 13 January 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Halfmann P.J., Iida S., Iwatsuki-Horimoto K., Maemura T., Kiso M., Scheaffer S.M., Darling T.L., Joshi A., Loeber S., Singh G., et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature. 2022;603:687&#x2013;692. doi: 10.1038/s41586-022-04441-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04441-6</ArticleId><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>VanBlargan L.A., Errico J.M., Halfmann P.J., Zost S.J., Crowe J.E., Jr., Purcell L.A., Kawaoka Y., Corti D., Fremont D.H., Diamond M.S. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. 2022;28:490&#x2013;495. doi: 10.1038/s41591-021-01678-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01678-y</ArticleId><ArticleId IdType="pmc">PMC8767531</ArticleId><ArticleId IdType="pubmed">35046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekliz M., Adea K., Vetter P., Eberhardt C.S., Hosszu-Fellous K., Vu D.L., Puhach O., Essaidi-Laziosi M., Waldvogel-Abramowski S., Stephan C., et al. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. Nat. Commun. 2022;13:3840. doi: 10.1038/s41467-022-31556-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31556-1</ArticleId><ArticleId IdType="pmc">PMC9253337</ArticleId><ArticleId IdType="pubmed">35787633</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W., Li Q., Wang P., An R., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657&#x2013;663. doi: 10.1038/s41586-021-04385-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan D.J., Franchini M., Joyner M.J., Casadevall A., Focosi D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat. Commun. 2022;13:6478. doi: 10.1038/s41467-022-33864-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33864-y</ArticleId><ArticleId IdType="pmc">PMC9617541</ArticleId><ArticleId IdType="pubmed">36309490</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Liao H., Meng Y., Li W., Han P., Liu K., Wang Q., Li D., Zhang Y., Wang L., et al. Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell. 2022;185:2952&#x2013;2960.e10. doi: 10.1016/j.cell.2022.06.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.023</ArticleId><ArticleId IdType="pmc">PMC9212699</ArticleId><ArticleId IdType="pubmed">35809570</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki R., Yamasoba D., Kimura I., Wang L., Kishimoto M., Ito J., Morioka Y., Nao N., Nasser H., Uriu K., et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603:700&#x2013;705. doi: 10.1038/s41586-022-04462-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Ferreira I.A.T.M., Abdullahi A., Saito A., Kimura I., Yamasoba D., Kemp S.A., Goonawardane N., Papa G., Fatihi S., et al. SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv. 2021 doi: 10.1101/2021.12.17.473248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.17.473248</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., Zlitni S., Brooks E.F., Vance S.E., Dahlen A., Hedlin H., Park R.M., Han A., Schmidtke D.T., Verma R., et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3:371&#x2013;387.e9. doi: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang K.K., Kaczmarek M.E., Dallari S., Chen Y.-H., Tada T., Axelrad J., Landau N.R., Stapleford K.A., Cadwell K. Variable susceptibility of intestinal organoid&#x2013;derived monolayers to SARS-CoV-2 infection. PLoS Biol. 2022;20:e3001592. doi: 10.1371/journal.pbio.3001592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001592</ArticleId><ArticleId IdType="pmc">PMC9004766</ArticleId><ArticleId IdType="pubmed">35358182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang R., Gomez Castro M.F., McCune B.T., Zeng Q., Rothlauf P.W., Sonnek N.M., Liu Z., Brulois K.F., Wang X., Greenberg H.B., et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 2020;5:eabc3582. doi: 10.1126/sciimmunol.abc3582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc3582</ArticleId><ArticleId IdType="pmc">PMC7285829</ArticleId><ArticleId IdType="pubmed">32404436</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Beumer J., van der Vaart J., Knoops K., Puschhof J., Breugem T.I., Ravelli R.B.G., Paul van Schayck J., Mykytyn A.Z., Duimel H.Q., et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369:50&#x2013;54. doi: 10.1126/science.abc1669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc1669</ArticleId><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Chu M., Zhong F., Tan X., Tang G., Mai J., Lai N., Guan C., Liang Y., Liao G. Digestive symptoms of COVID-19 and expression of ACE2 in digestive tract organs. Cell Death Discov. 2020;6:76. doi: 10.1038/s41420-020-00307-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-020-00307-w</ArticleId><ArticleId IdType="pmc">PMC7417862</ArticleId><ArticleId IdType="pubmed">32818075</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes Sousa S., Kleiton de Sousa A., Maria Carvalho Pereira C., Sofia Miranda Loiola Araujo A., de Aguiar Magalhaes D., Vieira de Brito T., Barbosa A. SARS-CoV-2 infection causes intestinal cell damage: Role of interferon&#x2019;s imbalance. Cytokine. 2022;152:155826. doi: 10.1016/j.cyto.2022.155826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2022.155826</ArticleId><ArticleId IdType="pmc">PMC8828414</ArticleId><ArticleId IdType="pubmed">35158258</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss S.R., Leibowitz J.L. Coronavirus pathogenesis. Adv. Virus Res. 2011;81:85&#x2013;164. doi: 10.1016/B978-0-12-385885-6.00009-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385885-6.00009-2</ArticleId><ArticleId IdType="pmc">PMC7149603</ArticleId><ArticleId IdType="pubmed">22094080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Muller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465&#x2013;469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen C., Zhu S., Shu C., Wang D., Song J., Song Y., Zhen W., Feng Z., Wu G., et al. Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19) China CDC Wkly. 2020;2:123&#x2013;124. doi: 10.46234/ccdcw2020.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2020.033</ArticleId><ArticleId IdType="pmc">PMC8392928</ArticleId><ArticleId IdType="pubmed">34594837</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu E., Xie Y., Al-Aly Z. Long-term gastrointestinal outcomes of COVID-19. Nat. Commun. 2023;14:983. doi: 10.1038/s41467-023-36223-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36223-7</ArticleId><ArticleId IdType="pmc">PMC9992516</ArticleId><ArticleId IdType="pubmed">36882400</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.C., Devason A.S., Umana I.C., Cox T.O., Dohnalova L., Litichevskiy L., Perla J., Lundgren P., Etwebi Z., Izzo L.T., et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186:4851&#x2013;4867.e20. doi: 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadlier C., Albrich W.C., Neogi U., Lunjani N., Horgan M., O&#x2019;Toole P.W., O&#x2019;Mahony L. Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19. Allergy. 2022;77:1623&#x2013;1625. doi: 10.1111/all.15253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15253</ArticleId><ArticleId IdType="pmc">PMC9111264</ArticleId><ArticleId IdType="pubmed">35150456</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado D.M., Son J., Thackray L.B., Gomez Castro M.F., Prasad S., Cui X., Sonnek N.M., Diamond M.S., Ding S., Ciorba M.A. Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice. Inflamm. Bowel Dis. 2021;28:318&#x2013;321. doi: 10.1093/ibd/izab274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izab274</ArticleId><ArticleId IdType="pmc">PMC8690199</ArticleId><ArticleId IdType="pubmed">34849936</ArticleId></ArticleIdList></Reference><Reference><Citation>VanDussen K.L., Marinshaw J.M., Shaikh N., Miyoshi H., Moon C., Tarr P.I., Ciorba M.A., Stappenbeck T.S. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. Gut. 2015;64:911&#x2013;920. doi: 10.1136/gutjnl-2013-306651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2013-306651</ArticleId><ArticleId IdType="pmc">PMC4305344</ArticleId><ArticleId IdType="pubmed">25007816</ArticleId></ArticleIdList></Reference><Reference><Citation>Case J.B., Bailey A.L., Kim A.S., Chen R.E., Diamond M.S. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology. 2020;548:39&#x2013;48. doi: 10.1016/j.virol.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7293183</ArticleId><ArticleId IdType="pubmed">32838945</ArticleId></ArticleIdList></Reference><Reference><Citation>Masood K.I., Yameen M., Ashraf J., Shahid S., Mahmood S.F., Nasir A., Nasir N., Jamil B., Ghanchi N.K., Khanum I., et al. Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome. Sci. Rep. 2021;11:22958. doi: 10.1038/s41598-021-02489-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-02489-4</ArticleId><ArticleId IdType="pmc">PMC8617268</ArticleId><ArticleId IdType="pubmed">34824360</ArticleId></ArticleIdList></Reference><Reference><Citation>Santer D.M., Li D., Ghosheh Y., Zahoor M.A., Prajapati D., Hansen B.E., Tyrrell D.L.J., Feld J.J., Gehring A.J. Interferon-lambda treatment accelerates SARS-CoV-2 clearance despite age-related delays in the induction of T cell immunity. Nat. Commun. 2022;13:6992. doi: 10.1038/s41467-022-34709-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34709-4</ArticleId><ArticleId IdType="pmc">PMC9667439</ArticleId><ArticleId IdType="pubmed">36385011</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena K., Simon L.M., Zeng X.L., Blutt S.E., Crawford S.E., Sastri N.P., Karandikar U.C., Ajami N.J., Zachos N.C., Kovbasnjuk O., et al. A paradox of transcriptional and functional innate interferon responses of human intestinal enteroids to enteric virus infection. Proc. Natl. Acad. Sci. USA. 2017;114:E570&#x2013;E579. doi: 10.1073/pnas.1615422114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1615422114</ArticleId><ArticleId IdType="pmc">PMC5278484</ArticleId><ArticleId IdType="pubmed">28069942</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Yang W., Roy S., Liu H., Roberts R.M., Wang L., Shi L., Ma W. Tight junction protein occludin is an internalization factor for SARS-CoV-2 infection and mediates virus cell-to-cell transmission. Proc. Natl. Acad. Sci. USA. 2023;120:e2218623120. doi: 10.1073/pnas.2218623120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2218623120</ArticleId><ArticleId IdType="pmc">PMC10151465</ArticleId><ArticleId IdType="pubmed">37068248</ArticleId></ArticleIdList></Reference><Reference><Citation>Biering S.B., Gomes de Sousa F.T., Tjang L.V., Pahmeier F., Zhu C., Ruan R., Blanc S.F., Patel T.S., Worthington C.M., Glasner D.R., et al. SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-beta signaling. Nat. Commun. 2022;13:7630. doi: 10.1038/s41467-022-34910-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34910-5</ArticleId><ArticleId IdType="pmc">PMC9734751</ArticleId><ArticleId IdType="pubmed">36494335</ArticleId></ArticleIdList></Reference><Reference><Citation>Volcic M., Nchioua R., Pastorio C., Zech F., Read C., Walther P., Kirchhoff F. Attenuated replication and damaging effects of SARS-CoV-2 Omicron variants in an intestinal epithelial barrier model. bioRxiv. 2024 doi: 10.1101/2024.02.28.582510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.02.28.582510</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Fari&#xf1;as M., Tokuyama M., Wei G., Huang R., Livanos A., Jha D., Levescot A., Irizar H., Kosoy R., Cording S., et al. Intestinal Inflammation Modulates the Expression of ACE2 and TMPRSS2 and Potentially Overlaps With the Pathogenesis of SARS-CoV-2-related Disease. Gastroenterology. 2020;160:287&#x2013;301. doi: 10.1053/j.gastro.2020.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.09.029</ArticleId><ArticleId IdType="pmc">PMC7516468</ArticleId><ArticleId IdType="pubmed">32980345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro R.C., Brenner E.J., Gearry R.B., Kaplan G.G., Kissous-Hunt M., Lewis J.D., Ng S.C., Rahier J.F., Reinisch W., Steinwurz F., et al. Effect of IBD medications on COVID-19 outcomes: Results from an international registry. Gut. 2021;70:725&#x2013;732. doi: 10.1136/gutjnl-2020-322539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322539</ArticleId><ArticleId IdType="pmc">PMC8136807</ArticleId><ArticleId IdType="pubmed">33082265</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gu S., Chen Y., Lu H., Shi D., Guo J., Wu W.-R., Yang Y., Li Y., Xu K.-J., et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022;71:222&#x2013;225. doi: 10.1136/gutjnl-2021-324090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324090</ArticleId><ArticleId IdType="pmc">PMC8666823</ArticleId><ArticleId IdType="pubmed">33833065</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., Yeoh Y.K., Lui G.C., Ng S.S.S., Zhang F., Li A.Y.L., Lu W., Hui D.S., et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin Gimenez V.M., Modrego J., Gomez-Garre D., Manucha W., de Las Heras N. Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy. Int. J. Mol. Sci. 2023;24:12249. doi: 10.3390/ijms241512249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241512249</ArticleId><ArticleId IdType="pmc">PMC10419057</ArticleId><ArticleId IdType="pubmed">37569625</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>